Afluria serves as a vital tool in the prevention of influenza, commonly referred to as the flu. It is indicated for individuals aged 6 months and older, offering protection against the flu virus strains included in the vaccine for the current flu season. The vaccine is particularly recommended for individuals who are at higher risk of developing severe complications from the flu, including:

Individuals aged 65 years and older, who may have weaker immune systems and are more susceptible to flu-related complications such as pneumonia. Infants and children under the age of 5, who may not have fully developed immune systems and are at increased risk of severe flu symptoms.

Pregnant individuals, who experience changes in their immune system that make them more susceptible to severe illness from the flu. Those with chronic health conditions such as asthma, diabetes, heart disease, or weakened immune systems, who are at higher risk of complications if they contract the flu.

How it works 

Afluria operates by leveraging the body’s natural immune response to protect against influenza infection. The vaccine contains inactivated strains of the influenza virus, meaning the viruses are not live and cannot cause illness. When administered via injection into the muscle, Afluria introduces these inactivated virus strains to the immune system.

Upon encountering the inactivated viruses, the immune system recognizes them as foreign invaders and initiates a defensive response. Specialized cells within the immune system, known as B cells, produce antibodies specific to the influenza virus strains present in the vaccine. These antibodies serve as a defense mechanism, priming the immune system to recognize and combat the virus if the individual is later exposed to live influenza viruses.

Pain, Redness, or Swelling at the Injection Site: Some individuals may experience tenderness, redness, or swelling at the site where the vaccine was administered. 

Mild Fever: A low-grade fever is a common reaction to vaccination and may occur within a day or two after receiving Afluria. Fever is the body’s natural response to the vaccine as it stimulates the immune system.

Headache: Headaches are among the common side effects reported after vaccination with Afluria. They are usually mild and temporary.

Fatigue: Some individuals may feel tired or fatigued after receiving the vaccine. This is often transient and resolves without intervention.

Muscle Aches: Muscle aches or soreness may occur, particularly in the arms or legs where the vaccine was administered. This is a common side effect and typically resolves within a few days.

Before receiving Afluria, individuals should be aware of certain precautions and warnings to ensure the safe and effective administration of the vaccine. These include:

Individuals with a history of severe allergic reactions (anaphylaxis) to any component of the Afluria vaccine or to a previous dose of influenza vaccine should not receive Afluria. It’s essential to inform healthcare providers of any known allergies, including those to eggs or other vaccine components, before vaccination.

Afluria should be administered with caution to individuals with a history of Guillain-Barré Syndrome (GBS), a rare neurological disorder characterized by muscle weakness. While the association between influenza vaccination and GBS is rare, individuals with a history of GBS should discuss the potential risks and benefits of vaccination with their healthcare provider.

Afluria may not be as effective in individuals with weakened immune systems due to certain medical conditions or treatments. Healthcare providers should evaluate the risks and benefits of vaccination in these individuals and may recommend alternative vaccination strategies.

Drugs that suppress the immune system, like corticosteroids or chemotherapy agents, may reduce the effectiveness of Afluria. Healthcare providers might adjust the timing of vaccination or recommend additional doses for individuals on immunosuppressive therapy.

Biologic medications, such as monoclonal antibodies or targeted immunosuppressive drugs, could impact the immune response to Afluria. Healthcare providers may assess the individual’s treatment plan to determine the best vaccination approach.

Medications used to treat influenza, like oseltamivir or zanamivir, don’t interfere with Afluria. Individuals receiving antiviral treatment can safely get vaccinated to prevent future flu infections.

Afluria is typically administered as a single dose each flu season to individuals aged 6 months and older. The recommended dosage may vary based on age, vaccination history, and individual health factors. For most individuals, a single injection of Afluria provides sufficient protection against influenza for the duration of the flu season.

Dosage adjustments may be necessary for certain populations, such as young children or individuals with specific medical conditions. Healthcare providers follow guidelines from public health authorities, such as the Centers for Disease Control and Prevention (CDC), to determine the appropriate dosage and vaccination schedule for each individual.

Healthcare providers may also recommend additional doses or booster shots in certain circumstances, such as during vaccine mismatches or in response to emerging flu strains. It’s essential for individuals to consult with their healthcare provider to determine the most appropriate dosage and vaccination schedule based on their age, health status, and risk factors.

Afluria is available by prescription and is typically administered by healthcare professionals in clinics, pharmacies, or other healthcare settings.

 It is essential to consult with a healthcare provider to determine if Afluria is appropriate for you and to receive guidance on vaccination timing and dosing. 

In some cases, Afluria may be available without a prescription at community vaccination clinics or other designated locations during flu season.

• Afluria is available by prescription from healthcare providers.
• It is typically administered in clinics, pharmacies, or other healthcare settings.
• Healthcare providers evaluate individual eligibility and vaccination needs before prescribing Afluria.
• Prescription requirement ensures appropriate administration and monitoring of the vaccine.
• Community vaccination clinics or designated locations may offer Afluria without a prescription during flu season.
• Individuals should consult with their healthcare provider to determine if Afluria is suitable for them and receive guidance on vaccination timing and dosing.